Renal Cell Carcinoma: Emerging Data in Non–Clear Cell Disease

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged focus on the management of non–clear cell renal cell carcinoma, a group of histologies that has historically been underrepresented in large phase 3 trials. Dr. Ged discusses how limited evidence has traditionally made treatment selection in non–clear cell renal cell carcinoma more challenging compared with clear cell disease. The conversation highlights emerging data from studies such as KEYNOTE-B61, which evaluate pembrolizumab-based combinations in these populations and begin to address this evidence gap. Dr. Ged explains how these findings are starting to inform clinical decision-making by providing greater confidence in the use of immunotherapy-based strategies across diverse histologies. The discussion also emphasizes the importance of tailoring treatment to individual patient and disease characteristics, while acknowledging that further research is still needed to refine optimal approaches in non–clear cell renal cell carcinoma.